Marketers and The Myth of Perfect Control

Marketers and The Myth of Perfect Control

You're not broken. I promise.


I can understand why you would think you are, though. After all, you're an expert in yourself. Like a fine painter, you're so familiar with your subject matter that you quickly notice when things are off by a hair. Leonardo da Vinci would surely notice if Lisa had her hands crossed incorrectly, and so you notice a little extra puffiness in your cheeks or a tiny blemish the size of a pinhead on the side of your nostril.

But the dark side of expertise is obsession. And there are few obsessions more tempting than envy and self-criticism. It’s part of the human condition. But there is no worse place to be. Self-pity is quicksand, and will keep you mired and focused inward, contemplating your slightly-less-than-perfect navel.

Today, with technology bringing more of the world under our control, envy and self-pity can lead to never-ending consumption and modification. There is always another watch you can buy, or wine you can drink, to feel a little more worthwhile and confident. In 1800, if you were born with a less than flattering nose, you had to deal with it. In 2015, you can get a masterful nostril reshaping done to the specifications of your favorite celebrity.

In psychology, this is called your locus of control. If you believe you can control what happens to you in life, you have what’s called an internal locus of control. If you believe you’re at the mercy of outside forces, you have what’s called an external locus of control. And in the 21st century, everyone is being internalized. This is a blessing for humanity, but a control freak’s nightmare. While you might have learned how to come to peace with the uncertainty of life and your imperfections in the 19th or 18th centuries, today you can decide to successfully wage all-out war against everything you don’t like.

This is partly due to true technological advancements, and partly due to devilishly effective marketing. Technological advancements in computing, medicine, agriculture, mobile phones, and so forth have genuinely given us control over much of our lives. But consumer marketing, pioneered by Edward Bernays in the early 20th century, has given us an even greater illusion of control.

Each product in our lives has been associated with a happy outcome or a positive image. Toilet paper is no longer just toilet paper. It’s a kid pleaser and a home saver. In ad after ad we see a happy father pull a 12-pack of extra-ply TP off the shelf while his nearby children cheer and smile. Consciously we see this ad as ridiculous. Subconsciously, though, a connection has been made between the product and our happy children. “Buy this product and your kids will be contented” seems to be the hidden message. And so we purchase product after product with expertly crafted associations and branding. Consciously, we don’t really expect anything magical to happen. Over time, however, we might notice ourselves getting a bit frustrated with the world. The kids aren’t happy. The boss doesn’t respond the way we’d like to our presentation. A new freckle or zit has popped up on the nose.

This is life. It’s uncertain, wild, and mostly uncontrollable. It’s imperfect and will always be — and so are you. We all are. In our never-ending quest to create our ideal selves and life, let’s not forget that true perfection comes when we change the things we can, and accept the rest. Every great hero has a flaw.

U.S. Navy controls inventions that claim to change "fabric of reality"

Inventions with revolutionary potential made by a mysterious aerospace engineer for the U.S. Navy come to light.

U.S. Navy ships

Credit: Getty Images
Surprising Science
  • U.S. Navy holds patents for enigmatic inventions by aerospace engineer Dr. Salvatore Pais.
  • Pais came up with technology that can "engineer" reality, devising an ultrafast craft, a fusion reactor, and more.
  • While mostly theoretical at this point, the inventions could transform energy, space, and military sectors.
Keep reading Show less

Why so gassy? Mysterious methane detected on Saturn’s moon

Scientists do not know what is causing the overabundance of the gas.

An impression of NASA's Cassini spacecraft flying through a water plume on the surface of Saturn's moon Enceladus.

Credit: NASA
Surprising Science
  • A new study looked to understand the source of methane on Saturn's moon Enceladus.
  • The scientists used computer models with data from the Cassini spacecraft.
  • The explanation could lie in alien organisms or non-biological processes.
Keep reading Show less

CRISPR therapy cures first genetic disorder inside the body

It marks a breakthrough in using gene editing to treat diseases.

Credit: National Cancer Institute via Unsplash
Technology & Innovation

This article was originally published by our sister site, Freethink.

For the first time, researchers appear to have effectively treated a genetic disorder by directly injecting a CRISPR therapy into patients' bloodstreams — overcoming one of the biggest hurdles to curing diseases with the gene editing technology.

The therapy appears to be astonishingly effective, editing nearly every cell in the liver to stop a disease-causing mutation.

The challenge: CRISPR gives us the ability to correct genetic mutations, and given that such mutations are responsible for more than 6,000 human diseases, the tech has the potential to dramatically improve human health.

One way to use CRISPR to treat diseases is to remove affected cells from a patient, edit out the mutation in the lab, and place the cells back in the body to replicate — that's how one team functionally cured people with the blood disorder sickle cell anemia, editing and then infusing bone marrow cells.

Bone marrow is a special case, though, and many mutations cause disease in organs that are harder to fix.

Another option is to insert the CRISPR system itself into the body so that it can make edits directly in the affected organs (that's only been attempted once, in an ongoing study in which people had a CRISPR therapy injected into their eyes to treat a rare vision disorder).

Injecting a CRISPR therapy right into the bloodstream has been a problem, though, because the therapy has to find the right cells to edit. An inherited mutation will be in the DNA of every cell of your body, but if it only causes disease in the liver, you don't want your therapy being used up in the pancreas or kidneys.

A new CRISPR therapy: Now, researchers from Intellia Therapeutics and Regeneron Pharmaceuticals have demonstrated for the first time that a CRISPR therapy delivered into the bloodstream can travel to desired tissues to make edits.

We can overcome one of the biggest challenges with applying CRISPR clinically.

—JENNIFER DOUDNA

"This is a major milestone for patients," Jennifer Doudna, co-developer of CRISPR, who wasn't involved in the trial, told NPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," she continued.

What they did: During a phase 1 clinical trial, Intellia researchers injected a CRISPR therapy dubbed NTLA-2001 into the bloodstreams of six people with a rare, potentially fatal genetic disorder called transthyretin amyloidosis.

The livers of people with transthyretin amyloidosis produce a destructive protein, and the CRISPR therapy was designed to target the gene that makes the protein and halt its production. After just one injection of NTLA-2001, the three patients given a higher dose saw their levels of the protein drop by 80% to 96%.

A better option: The CRISPR therapy produced only mild adverse effects and did lower the protein levels, but we don't know yet if the effect will be permanent. It'll also be a few months before we know if the therapy can alleviate the symptoms of transthyretin amyloidosis.

This is a wonderful day for the future of gene-editing as a medicine.

—FYODOR URNOV

If everything goes as hoped, though, NTLA-2001 could one day offer a better treatment option for transthyretin amyloidosis than a currently approved medication, patisiran, which only reduces toxic protein levels by 81% and must be injected regularly.

Looking ahead: Even more exciting than NTLA-2001's potential impact on transthyretin amyloidosis, though, is the knowledge that we may be able to use CRISPR injections to treat other genetic disorders that are difficult to target directly, such as heart or brain diseases.

"This is a wonderful day for the future of gene-editing as a medicine," Fyodor Urnov, a UC Berkeley professor of genetics, who wasn't involved in the trial, told NPR. "We as a species are watching this remarkable new show called: our gene-edited future."

Quantcast